Atherosclerotic Risk Factors, Prevention, and Medical Optimization

4.1Guidelines and risk sequencing

Medical optimization starts by deciding which clinical problem is actually in front of the team. An asymptomatic adult with risk factors is not the same patient as a person with symptomatic peripheral arterial disease, and neither is identical to the patient being prepared for a vascular operation. The 2019 ACC/AHA primary-prevention guideline, the 2021 ESC cardiovascular-prevention guideline, the 2024 ACC/AHA PAD guideline, and the 2024 ESC peripheral arterial and aortic disease guideline all organise care around risk, risk-factor treatment, smoking, exercise, and antithrombotic decisions, but they apply those decisions to different populations and with society-specific thresholds ACC/AHA 2024 · ACC/AHA 2024 · ESC 2024 · ESC 2021 · ACC/AHA primary prevention 2019. Documentation should therefore specify whether the patient is in primary prevention, established PAD secondary prevention, or a perioperative vascular pathway, as this context determines how lipid, blood-pressure, diabetes, antithrombotic, smoking-cessation, and exercise decisions are interpreted.

For the patient without established vascular disease, risk estimation is the starting conversation rather than a diagnostic label. SCORE2 was designed to estimate cardiovascular risk in European prevention practice, while the PREVENT family and pooled-cohort-equation comparisons show how modern calculators can change statin allocation and risk classification in contemporary populations Validation Framingham General 2023 · Comparison pooled cohort 2024 · SCORE2 risk prediction 2021. In that setting, the estimated risk number helps determine whether the discussion is mainly lifestyle, moderate-intensity pharmacologic prevention, or more intensive risk-factor treatment. The number still has to be interpreted through age, sex, kidney disease, diabetes, smoking, family history, social context, frailty, and patient preference; it is a decision aid, not a substitute for clinical judgment.

Once symptomatic PAD is established, the prevention frame changes. A patient with claudication, chronic limb-threatening ischemia, prior limb revascularization, or another convincing PAD phenotype should generally be treated as having established atherosclerotic disease even if a general calculator appears reassuring. Newer work with PREVENT, lipoprotein(a), and cohort-based risk tools reinforces the same clinical caution: risk equations can refine baseline estimates, but they may not fully capture vascular-territory risk, competing limb risk, or the risk carried by established atherosclerotic disease AHA PREVENT Equations 2025. Primary-prevention calculators should therefore not be used to de-escalate treatment intensity in patients with established symptomatic limb disease.

The perioperative frame is layered on top rather than replacing the prevention frame. Before carotid, aortic, lower-extremity, or access-related vascular surgery, the clinician still has to ask whether the patient is on the correct prevention pathway, but the timing of escalation changes. A stable outpatient visit may be the right time to intensify lipid therapy, adjust antihypertensives, start smoking-cessation pharmacotherapy, and prescribe walking exercise; the days before a major operation may instead require prioritising medication reconciliation, renal protection, bleeding risk, hemodynamic stability, and clear post-discharge follow-up. The current guidelines remain essential, but they have to be translated into a sequence that a real patient can tolerate and a real team can execute ACC/AHA 2024 · ESC 2024 · ESC 2021 · ACC/AHA primary prevention 2019.

4.2Lipid, blood-pressure, and cardiometabolic treatment lanes

Lipid management follows a stepwise escalation. A guideline-directed statin is the foundation in the ACC/AHA cholesterol guideline and the ESC/EAS dyslipidaemia guideline, with intensity determined by whether the patient is in primary prevention, very-high-risk prevention, or established vascular disease ESC 2019 · AHA/ACC 2018. During follow-up, the clinician must assess statin tolerance, adherence, the achieved LDL-C response, and the next step if the agreed target is not reached. That framing prevents therapeutic drift, especially in patients who move between the vascular ward, primary care, cardiology, diabetology, and rehabilitation.

Ezetimibe is the usual first non-statin addition when a patient remains above the goal defined by the relevant guideline and clinical frame. IMPROVE-IT established that adding ezetimibe to statin therapy after acute coronary syndrome reduced cardiovascular events in a high-risk population, and that result is the clinical backbone for treating residual LDL-C as modifiable rather than as a reason to stop at a maximally tolerated statin Ezetimibe Added Statin 2015. Contemporary meta-analyses of statin-plus-ezetimibe strategies reinforce the practical value of combination lipid lowering, but the vascular clinician should still document the patient’s risk category, current LDL-C response, statin tolerance, and reason for escalation rather than simply listing drugs Alternative LDL Cholesterol-Lowering 2025 · Impact Lipid-Lowering Combination 2025.

PCSK9 inhibition belongs on the same ladder for selected patients with persistent high residual risk. FOURIER showed that evolocumab reduced cardiovascular events in patients with established cardiovascular disease, and ODYSSEY OUTCOMES showed that alirocumab reduced events after acute coronary syndrome; together, these trials support further LDL-C lowering when statin and ezetimibe therapy have not achieved the desired risk reduction in a high-risk patient Alirocumab Cardiovascular Outcomes 2018 · Evolocumab Clinical Outcomes 2017. Network and comparative synthesis evidence extends the comparison across PCSK9 and ezetimibe strategies, but therapy must still be matched to baseline risk, LDL-C response, comorbidity, cost, access, and adherence PCSK9 inhibitors ezetimibe 2022. JUPITER remains important for primary-prevention reasoning because it showed that rosuvastatin can reduce vascular events in patients selected by elevated inflammatory risk despite LDL-C values that might otherwise appear less compelling Rosuvastatin Prevent Vascular 2008. In a vascular surgery text, the point is not to convert hs-CRP into an automatic treatment trigger, but to show why residual risk cannot be judged from LDL-C alone.

Blood-pressure treatment is another risk-reduction lane, and the evidence warns against copying a single target across all vascular patients. SPRINT showed benefit from intensive systolic blood-pressure lowering in selected non-diabetic adults at high cardiovascular risk, whereas ACCORD BP did not reproduce the same overall cardiovascular benefit for the same intensive target in patients with type 2 diabetes Randomized Trial Intensive 2015 · Effects Intensive Blood-Pressure 2010. The ACC/AHA hypertension guideline and European hypertension guidance therefore have to be applied through the patient’s phenotype: frailty, falls, orthostatic symptoms, kidney function, coronary disease, heart failure, cognitive status, and the timing of vascular intervention all influence whether a lower target is safe and realistic ESC 2023 · ACC/AHA 2017. HOPE-3 adds a prevention lesson from intermediate-risk adults: combined statin and blood-pressure lowering can reduce events even when the entry point is global risk rather than a single extreme measurement Blood-Pressure Lowering Intermediate-Risk 2016.

Diabetes treatment has also moved from glucose-only thinking to vascular-risk thinking. In patients with type 2 diabetes and vascular disease or high cardiovascular risk, SGLT2 inhibitors and GLP-1 receptor agonists are chosen partly for cardiovascular and renal effects, in addition to hemoglobin A1c lowering. EMPA-REG OUTCOME showed cardiovascular benefit with empagliflozin, DECLARE-TIMI 58 informed the dapagliflozin cardiovascular-outcomes evidence base, and the LEADER and SUSTAIN-6 trials showed cardiovascular benefits with liraglutide and semaglutide in high-risk diabetes populations Dapagliflozin Cardiovascular Outcomes 2019 · Liraglutide Cardiovascular Outcomes 2016 · Semaglutide Cardiovascular Outcomes 2016 · Empagliflozin Cardiovascular Outcomes 2015. For the vascular surgeon, the operative implication is straightforward: diabetes medication choice, renal trajectory, volume status, hypoglycaemia risk, wound risk, and planned intervention should be assessed together rather than handed off as unrelated problems.

4.3PAD-specific antithrombotic and lifestyle decisions

Antithrombotic prevention in vascular patients involves three distinct contexts. The first is primary prevention: should an adult without established vascular disease start aspirin to prevent a first event? ASPREE, ASCEND, and ARRIVE showed that any vascular benefit of aspirin in contemporary primary-prevention populations is limited by bleeding, and the 2022 USPSTF recommendation therefore argues against routine initiation of aspirin for primary prevention in many adults USPSTF 2022 · Use aspirin reduce 2018 · Effects Aspirin Primary 2018 · Effect Aspirin 2018. That evidence should not be misapplied to a patient who already has symptomatic PAD, because the clinical context has changed.

The second question is stable atherosclerotic disease, including stable PAD. COMPASS tested very-low-dose rivaroxaban plus aspirin against aspirin-based strategies in stable cardiovascular disease and showed fewer major cardiovascular events with the dual-pathway regimen, while the PAD analysis showed reduction in limb as well as cardiovascular events at the cost of more major bleeding COMPASS 2018 · COMPASS 2017. Rather than a universal prescription for every patient with PAD, this requires a structured decision weighing symptomatic limb disease, prior revascularization, coronary or cerebrovascular overlap, renal function, age, anemia, gastrointestinal bleeding history, fall risk, concomitant anticoagulation, and the patient’s ability to understand and continue therapy.

The third question is the early period after lower-extremity revascularization. VOYAGER PAD enrolled patients after lower-extremity revascularization and showed that rivaroxaban plus aspirin reduced limb and cardiovascular events compared with aspirin monotherapy, again with a bleeding signal that must be considered before treatment is started VOYAGER PAD rivaroxaban 2020. The 2024 ACC/AHA and ESC PAD guidelines incorporate the primary-prevention aspirin trials, COMPASS, and VOYAGER PAD into context-specific pathways rather than a single antiplatelet rule ACC/AHA 2024 · ACC/AHA 2024 · ESC 2024. In practice, the note should say which context is being treated: no established vascular disease, stable PAD, or recent revascularization. Without that sentence, the next clinician cannot tell whether the regimen is deliberate or accidental.

Lifestyle modification is a biologically critical component of PAD management. Smoking cessation changes the vascular trajectory, and pharmacologic support combined with structured counseling is generally more effective than advice alone Cardiovascular metabolic changes 2025. The vascular team should record smoking status with the same seriousness as antithrombotic status: current use, prior quit attempts, nicotine or tobacco product type, pharmacologic plan, counseling plan, and follow-up interval. A patient who has undergone technically successful revascularization but continues smoking remains exposed to accelerated restenosis, cardiovascular events, wound complications, and disease progression; the operation does not cancel the risk factor.

Residual-risk markers complete the prevention assessment but should be handled carefully. Lipoprotein(a) is associated with higher atherosclerotic risk, and recent analyses linking lipoprotein(a), diabetes, body-fat distribution, interleukin-6, and cardiovascular outcomes show why residual risk may persist even after conventional risk factors are addressed Waist hip ratio 2025 · Association lipoprotein diabetes 2025 · Association Lipoprotein Interleukin-6 2025. These markers are useful for risk communication, family discussions, adherence, and selection of patients who may warrant specialist prevention input. They should not be presented as stand-alone treatment commands unless the treatment claim is supported by the relevant guideline or trial context ESC 2021 · ACC/AHA primary prevention 2019.

Walking therapy is equally practical. Supervised exercise is a first-line treatment for intermittent claudication where available, and structured home-based walking programs can improve walking performance and quality of life when supervised programs are inaccessible Effectiveness home-based walking 2025. PAD also carries systemic consequences beyond the limb, including kidney-outcome risk in cohort data, so exercise, blood pressure, diabetes, smoking, and renal surveillance should be considered together rather than as isolated clinic tasks Peripheral artery disease 2024. Revascularization is appropriate for selected patients with lifestyle-limiting symptoms, chronic limb-threatening ischemia, or anatomic indications, but it should not replace walking therapy when the primary problem is claudication physiology and deconditioning.

4.4Bringing the lanes together in practice

A comprehensive vascular prevention plan requires a structured sequence of decisions. The prevention frame should be named explicitly: asymptomatic primary prevention, established PAD, or a perioperative vascular pathway. That sentence determines how the clinician interprets risk calculators, lipid thresholds, blood-pressure goals, antithrombotic options, smoking treatment, and exercise therapy ACC/AHA 2024 · ESC 2024 · ESC 2021 · ACC/AHA primary prevention 2019. A primary-prevention patient may need calibrated risk estimation and shared decision-making about treatment intensity; a symptomatic PAD patient usually needs secondary-prevention intensity; a patient immediately before or after vascular intervention needs both long-term prevention and short-term procedural safety.

For lipid therapy, the clinical note should make escalation explicit: current statin and dose, tolerance, adherence, most recent lipid response, the target being used, and the next step if the target is not met. That next step may be statin intensification, ezetimibe, or PCSK9 inhibition depending on residual risk and the patient’s response to prior therapy AHA/ACC 2018. This is also the place to record why escalation is deferred, such as acute illness, intolerance, cost, access, competing frailty concerns, or the need to confirm adherence before adding another drug.

Blood pressure, diabetes, kidney function, and perioperative timing should be integrated rather than handled as isolated checkboxes. A lower blood-pressure target may be appropriate in a robust high-risk patient, but it can be harmful if it produces falls, renal injury, or symptomatic hypotension; SPRINT, ACCORD BP, ACC/AHA hypertension guidance, and European hypertension guidance support this patient-specific application rather than a universal target reflex ESC 2023 · ACC/AHA 2017 · Randomized Trial Intensive 2015 · Effects Intensive Blood-Pressure 2010. In diabetes, the medication plan should record whether cardiovascular and renal risk have been considered when selecting SGLT2 inhibitor or GLP-1 receptor agonist therapy, especially in patients with PAD, chronic kidney disease, heart failure, or planned intervention Dapagliflozin Cardiovascular Outcomes 2019 · Liraglutide Cardiovascular Outcomes 2016 · Semaglutide Cardiovascular Outcomes 2016 · Empagliflozin Cardiovascular Outcomes 2015.

The antithrombotic context should be defined separately from lipid, blood-pressure, and diabetes decisions. Aspirin for primary prevention, dual-pathway inhibition in stable PAD, and post-revascularization therapy after lower-extremity intervention are different decisions, and a regimen that is appropriate in one context may be inappropriate in another ACC/AHA 2024 · ACC/AHA 2024 · ESC 2024. Bleeding risk, concomitant anticoagulation, renal function, recent operation, anemia, coronary disease, and patient preference should be reassessed whenever the context changes.

The final line should make behavior and follow-up operational. Smoking cessation requires a specific treatment plan, and claudication management requires a structured exercise program. Residual-risk markers should be used to sharpen risk communication and adherence rather than to justify unsupported treatment claims. The durable vascular-prevention plan is therefore a living document: prevention frame, lipid ladder, blood-pressure and diabetes strategy, antithrombotic context, smoking and exercise plan, renal and metabolic trajectory, and a clear date for reassessment.